Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$201 Mln
P/E Ratio
--
P/B Ratio
1.17
Industry P/E
--
Debt to Equity
0.7
ROE
-0.34 %
ROCE
-18.38 %
Div. Yield
0 %
Book Value
1.44
EPS
-0.4
CFO
$-463.76 Mln
EBITDA
$-712.87 Mln
Net Profit
$-713.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| -14.44 | 18.46 | 0.00 | -38.54 | -26.19 | -34.87 | -26.41 |
|
BSE Sensex*
| 2.52 | 3.63 | 5.69 | 8.81 | 11.73 | 20.09 | 11.34 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| -41.30 | 46.67 | -74.14 | -69.99 | 58.06 | 2.82 | -42.71 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.67 | 200.22 | -- | 299.46 | |
| 7.12 | 191.83 | -- | -40.76 | |
| 1.66 | 229.53 | -- | -136.88 | |
| 0.60 | 19.23 | 5.35 | 33.7 |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma;... ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8 rue de la Croix Jarry, Paris, France, 75013 Read more
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
Headquarters
Paris
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cellectis SA - ADR stood at $ 384 Mln as on 31-Dec-24
The share price of Cellectis SA - ADR is $1.54 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Cellectis SA - ADR has given a return of -26.19% in the last 3 years.
Cellectis SA - ADR has a market capitalisation of $ 201 Mln as on 28-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Cellectis SA - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cellectis SA - ADR and enter the required number of quantities and click on buy to purchase the shares of Cellectis SA - ADR.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8 rue de la Croix Jarry, Paris, France, 75013
The CEO & director of Dr. Andre Choulika Ph.D.. is Cellectis SA - ADR, and CFO & Sr. VP is Dr. Andre Choulika Ph.D..
There is no promoter pledging in Cellectis SA - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
23
|
|
|
20
|
|
|
18
|
|
|
2
|
| Cellectis S.A. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-34.08
|
|
Operating margin(%)
|
-70.61
|
|
Net Margin(%)
|
-88.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cellectis SA - ADR was $0 Mln.
$0.01
(
